NCT01878266

Brief Summary

This Trial offers a reduction in patient burden, which is especially preferable in children with a poor compliance and poor performance status. This prospective randomized trial was extension to the previous controlled prospective study performed in Children's Cancer Hospital, Egypt and registered at clinicaltrials.com (NCT01635140). The ultimate aim of this work is to demonstrate noninferiority of the hypofractionated regimens relative to the conventional regimen in a controlled randomized clinical study.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
119

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2013

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

June 9, 2013

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 14, 2013

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2016

Completed
Last Updated

August 9, 2021

Status Verified

August 1, 2021

Enrollment Period

3.2 years

First QC Date

June 9, 2013

Last Update Submit

August 3, 2021

Conditions

Keywords

Diffuse Intrinsic Pontine Glioma (DIPG)Hypofractionated RadiotherapyRadiotherapyMedian survival

Outcome Measures

Primary Outcomes (1)

  • Median overall-free survival

    3 years

Secondary Outcomes (1)

  • Progression-free survival

    3 years

Study Arms (3)

Hypofractionated Arm (1)

EXPERIMENTAL

A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed

Radiation: Hypofractionated Arm (1)

Hypofractionated Arm (2)

EXPERIMENTAL

The same planning and treatment procedures will be performed. The total dose will be 4500 cGy in 15 fractions in 3 weeks; giving 300 cGy per fraction.

Radiation: Hypofractionated Arm (2)

Conventional Arm (3)

OTHER

The same planning and treatment procedures will be performed with 54.0 Gy in 30 fractions giving 1.8 Gy per fraction.

Radiation: Conventional Arm (3)

Interventions

A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week

Hypofractionated Arm (1)

The total dose to 4500 cGy in 15 fractions in 3 weeks

Hypofractionated Arm (2)

A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm

Conventional Arm (3)

Eligibility Criteria

Age2 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Newly diagnosed patients with a diffuse intrinsic brainstem glioma
  • Aged 2-18years,
  • Have symptoms for less than 3 months and at least two findings of the neurologic triad: cranial nerve deficits, ataxia, or long tract signs.
  • No performance criteria were required for entry onto the study.

You may not qualify if:

  • Children were not eligible if they had received any prior therapy other than steroids Treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Children's Cancer Hospital Egypt 57357

Cairo, 11441, Egypt

Location

MeSH Terms

Conditions

Diffuse Intrinsic Pontine Glioma

Condition Hierarchy (Ancestors)

GliomaNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueBrain Stem NeoplasmsInfratentorial NeoplasmsBrain NeoplasmsCentral Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 9, 2013

First Posted

June 14, 2013

Study Start

February 1, 2013

Primary Completion

May 1, 2016

Study Completion

May 1, 2016

Last Updated

August 9, 2021

Record last verified: 2021-08

Locations